Opendata, web and dolomites

NANO-GROWTH

An innovative, non-invasive and de-risked system to enable the transdermal delivery of fragile therapeutic compounds for a better management of painful diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANO-GROWTH project word cloud

Explore the words cloud of the NANO-GROWTH project. It provides you a very rough idea of what is the project "NANO-GROWTH" about.

heart    life    effect    million    release    subsequent    poor    inflicting    medication    financial    lab    suffering    travel    unbearable    painful    adverse    loaded    revenues    combined    integrity    rate    nerve    instance    hire    bloodstream    patients    dermal    damage    altogether    healthcare    mature    gain    creams    cancer    transdermally    helping    billion    topical    chronic    scarcity    administered    quality    compounds    mediated    patches    perspectives    stage    becomes    engineered    proven    biodegradation    transdermal    capsule    astracime    commercial    analgesics    protects    people    cure    persists    meds    customized    globally    age    therapeutic    disease    barriers    diabetes    longer    patch    innovative    efficiency    34    worldwide    41    saturated    leader    relief    secure    position    receive    safer    encloses    secures    overcomes    skin    nano    solution    turn    market    143    limitations    layers    neuropathy    severe    encapsulated    reduce    solutions    millions    consolidate    pain    diseases   

Project "NANO-GROWTH" data sheet

The following table provides information about the project.

Coordinator
ASTRACIME SL 

Organization address
address: CALLE MONTE AUSEVA 10 BAJO
city: OVIEDO
postcode: 33012
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.nanogrowth.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASTRACIME SL ES (OVIEDO) coordinator 50˙000.00

Map

 Project objective

Chronic pain affects 1.5 billion people worldwide, which means that pain affects more people than diabetes, heart disease and cancer combined. Since chronic pain persists for years, it becomes unbearable. Chronic pain is often the result from neuropathy (nerve damage), which increases with age but also due to chronic diseases. For instance, 34% of diabetes cases develop painful neuropathy, which means 143 million people affected globally. Since there is no cure, patients receive analgesics and other meds for pain relief. To avoid inflicting further pain, medication is administered transdermally using topical solutions like creams or patches. However, there are important barriers to the dermal delivery of analgesics: scarcity of viable compounds, high biodegradation rate, short effect, poor efficiency and severe adverse effects. In response, we at Astracime have developed an innovative solution that overcomes the limitations of transdermal pain relief. This NANO-GROWTH project aims to bring to market a unique dermal patch loaded with encapsulated therapeutic compounds. The customized capsule protects the integrity of the compounds as they travel through the skin layers and bloodstream. In addition, we have engineered the capsule to provide target-mediated release. Altogether, our method secures a longer and safer pain relief. After been proven at the lab scale, we now aim to take a step further towards the mature stage. Thus, in Phase 1 we aim to assess the subsequent steps needed to secure this project from all technical, commercial and financial perspectives. This project encloses significant growth potential for Astracime, allowing us to consolidate a leader position in the field of pain management. Indeed, we expect to gain €41 million in revenues and hire 30 new people in 5 years. In turn, this project will contribute to improve the quality of life of millions of patients suffering from pain, while helping to reduce costs to our saturated healthcare system.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANO-GROWTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANO-GROWTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More